With earnings yielding 1.06% versus 4.33% treasuries, Regeneron offers negative compensation for equity risk despite fortress-like balance sheet strength.
At $484 with a 1.06% earnings yield versus 4.33% treasuries, Regeneron demands faith in future breakthroughs while its ROIC collapsed from 14.96% to 1.97%.
Does the earnings yield offer a meaningful premium over bonds to justify equity risk?
This framework sees a deep negative spread with minimal growth to close it. The 1.06% earnings yield offers no compensation for equity risk versus treasuries, and 1% revenue growth suggests the yield gap will persist for years.
Does the price protect me from permanent loss of capital?
Applying this lens reveals conflicting signals. The DCF suggests significant undervaluation, but the 23.5x P/E and 65.8x EV/EBITDA multiples offer limited downside protection. The recent 59.8% decline has improved the margin but not to levels this framework considers safe.
Can this balance sheet survive a prolonged downturn?
This framework finds a fortress balance sheet. Net cash, minimal leverage, and strong coverage ratios provide years of runway even in severe downturns. The financial position offers the protection Graham sought.
Has management demonstrated consistent earnings over many years?
This framework sees a mixed but ultimately credible earnings record. The 82% beat rate demonstrates consistency, though declining growth and margin compression raise concerns about future earnings power.
Is Mr. Market creating opportunity through pessimism or danger through euphoria?
Mr. Market appears cautiously pessimistic. The asymmetric reaction to earnings and discount to DCF value suggest modest expectations, though the framework notes the concerning divergence between institutional accumulation and persistent insider selling.
Applying the Benjamin Graham framework reveals a business with fortress-like financial strength undermined by a collapsing return on capital and minimal margin of safety at current prices. The 1.06% earnings yield versus 4.33% treasuries demands heroic assumptions about future drug development success. While the balance sheet could weather any storm, the framework suggests waiting for Mr. Market to offer a price that compensates for both equity risk and the uncertainty inherent in biotechnology. At what price would Graham find the margin of safety sufficient for a business whose ROIC fell from 14.96% to 1.97%?
This analysis applies Benjamin Graham's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Benjamin Graham. Educational purposes only. Not financial advice.